A Phase I, Open-Label, Multiple Dose of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Lapatinib (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 21 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record
- 03 Jul 2014 Planned End Date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov record.